USPSTF Recommendation: Screening for Prostate Cancer
Interview with Alex H Krist, MD, MPH, Task Force member and co-author of Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - May 8, 2018 Category: General Medicine Authors: JAMA Network Source Type: podcasts
A New Prostate Cancer Screening Trial--Anything to See Here?
Yet another trial on risks and benefits of widespread PSA screening. Dr Kenny Lin puts it in perspective. (Source: Medscape Family Medicine Podcast)
Source: Medscape Family Medicine Podcast - March 16, 2018 Category: Primary Care Authors: Medscape Source Type: podcasts
JAMA Oncology : Standard vs Dose-Escalated Radiotherapy in Medium-Risk Prostate Cancer
Interview with Jeff Michalski, MD, author of Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - March 15, 2018 Category: General Medicine Authors: The JAMA Network Source Type: podcasts
APF in prostate cancer patients following radical prostatectomy: what happens next?
Whether or not patients with prostate cancer with adverse pathological features (APF) following radical prostatectomy should be offered radiotherapy immediately or wait for a high PSA reading has been...
Author: VJOncology
Added: 03/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 14, 2018 Category: Cancer & Oncology Source Type: podcasts
Case-based debate: is there evidence for local treatment in oligometastatic prostate cancer?
Patients with oligometastatic prostate cancer can be identified using highly advanced detection tools, such as positron emission tomography (PET) and full body magnetic resonance imaging (MRI). The qu...
Author: VJOncology
Added: 03/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 14, 2018 Category: Cancer & Oncology Source Type: podcasts
Addressing the issues faced in the ProtecT trial for patients with localized prostate cancer
The ProtecT trial (NCT02044172) was a study conducted between 1999 and 2009 that compared active monitoring, radical prostatectomy and radiotherapy for the management of clinically localized prostate ...
Author: VJOncology
Added: 03/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 14, 2018 Category: Cancer & Oncology Source Type: podcasts
10-year follow-up: the most effective treatment to ProtecT patients with localized prostate cancer?
An interesting update on the ProtecT trial (NCT02044172) was given by Freddie Hamdy, MBChB, LRCSPEd, LRCSEd, LRCPSGlasg, FRCSEd, MD, FRCSEd(Urol), FRCS, FMedSci, of the University of Oxford, Oxford, U...
Author: VJOncology
Added: 03/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 14, 2018 Category: Cancer & Oncology Source Type: podcasts
ProtecT trial: a battle between three treatments for patients with localized prostate cancer
Active monitoring, radical prostatectomy or radiotherapy? For men with clinically localized prostate cancer, which intervention has a disease-specific mortality advantage? Here, Freddie Hamdy, MBChB, ...
Author: VJOncology
Added: 03/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 14, 2018 Category: Cancer & Oncology Source Type: podcasts
Treating Back and Arthritis Pain With Opioids, Effects of 1-time PSA Screening on Prostate Cancer Mortality, Evidence for Using Vitamin and Mineral Supplements, Management of Thyroid Nodules, and more
Editor's Summary by Edward H. Livingston, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the March 6, 2018 issue (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - March 6, 2018 Category: General Medicine Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts
Head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic CRPC
The approval of enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) provided an important life-extending drug. Now the sequencing and uses of enzalutamide are bei...
Author: VJOncology
Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts
Differentiating aggressive vs. non-aggressive prostate cancer: the MiCheck GPC1 biomarker test
The addition of a new prostate cancer diagnostic test to inform clinicians and patients prior to the decision to biopsy would be beneficial, in conjunction with the traditional measures of PSA and DRE...
Author: VJOncology
Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts
How will new NSAAs impact clinical practice in prostate cancer?
Previously, patients with nonmetastatic castration-resistant prostate cancer (nmCRPRC) and the clinicians treating them had no therapeutic options to delay disease progression. Now there are two new n...
Author: VJOncology
Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts
Live long and PROSPER: enzalutamide for nmCRPC
There has previously been no approved treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC), due to a lack of evidence that any drug would prevent disease progression in this popul...
Author: VJOncology
Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts
